EUCTR2012-000512-29-ES进行中（未招募）不适用
Sonothrombolysis potentiated by microbubbles as a novel treatment of acute ischemic stroke: a prospective randomized pilot study - SONOVUE
Institut de Recerca Hospital Sant Pau0 个研究点开始时间: 2012年4月17日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The main inclusion criteria will be:
- •- All acute (<4,5 hours) ischemic stroke patients in the MCA territory (as depicted by head computed tomography CT or suspected by clinical data) with a disabling neurological deficit measurable by National Institute of Health Stroke Scale (NIHSS) score, that in the opinion of treating physicians require and meet accepted criteria of treatment with a standard 0.9mg/kg dose of iv rtPA.
- •- A documented occlusion of the middle cerebral artery (MCA) documented by TCD and/or angioCT.
- •-The patient or the legal representative signs the written consent to participate
- •-Age ? 18 years
- •-No significant improvement before treatment.
- •-The treatment is initiated within 90 minutes of hospital admission (door-to-needle time ? 90 minutes)
- •-There is no limitation regarding the NIHSS score. Scores under 5 are usually considered mild strokes, but they can be treated if the investigator believes that the measured deficit is important enough to cause disability. The investigator should weight benefits and risks when the score is under 5 and above 22.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
排除标准
- •Patients will be excluded if they have 1 or more of the following:
- •-severe stroke as indicated on baseline CT imaging or by a NIHSS score > 25
- •-evidence of hemorrhage on noncontrast head computed tomography CT),
- •-any other standard contraindication for intravenous rtPA therapy,
- •-primary treatment with intra-arterial thrombolysis,
- •-Previous Rankin scale score > 1 and NIHSS < 14 or previous Rankin scale score >2 and NIHSS ? 14
- •- Rapidly improving neurological symptoms such that the rate of improvement is expected to result in a NIHSS score of <4 at randomization
- •- Coexisting neurological diseases such as dementia or life-threatening illness.
- •- Seizure at symptom onset
- •- History or clinical presentation of intracranial hemorrhage, subarachnoid hemorrhage (even with a normal CT), arteriovenous malformation, aneurysm, spinal cord disease or cerebral neoplasm. Incidental meningioma and microbleeds per se are not exclusion criteria.
- •- Baseline blood glucose concentration less than 50 mg/dL or greater than 400 mg/dl, that cannot be corrected
- •- Uncontrolled hypertension, defined as systolic blood pressure >185 mm Hg or diastolic blood pressure >110 mm Hg on at least two separate occasions at least 10 min apart, or blood pressure that requires aggressive treatment to reduce it to within these limits
- •- Hereditary or acquired hemorrhagic diathesis
- •- Another stroke, a serious head injury or major surgery within the previous 3 month
- •-Platelet count < 100.000/mm3
- •-Hemorrhagic retinopathy
- •-Within 10 days of traumatic external heart massage, obstetrical delivery, recent puncture of a non-compressible blood-vessel
- •-Bacterial endocarditis, pericarditis
- •-Acute pancreatitis; documented ulcerative gastrointestinal disease during the last 3 months, esophageal varices
- •-Arterial aneurysm, arterial/venous malformations
- •-Neoplasm with increased bleeding risk
- •-Severe liver disease, including hepatic failure, cirrhosis, portal hypertension and active hepatitis
- •-Major surgery or significant trauma in past 3 months
- •- Contraindication to CT perfusion: Iodinated contrast allergy, renal insufficiency (elevated serum creatinine above normal laboratory levels at each center), non-collaborative patients, pregnancy
- •-Contraindication based on CT:
- •Intracerebral or subarachnoid haemorrhage, arteriovenous malformation, cerebral aneurysm, tumour or non-ischaemic lesions mimicking stroke.
- •Infarct core of more than 2/3 of middle cerebral artery territory or all of anterior cerebral artery territory.
- •Any other contraindication to the imaging technique.
研究者
相似试验
已完成
2 期
Sonothrombolysis Potentiated by Microbubbles for Acute Ischemic StrokeCerebrovascular StrokeNCT01678495Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau24
招募中
不适用
Safety and Efficacy of sonolysis therapy for treatment of microvascular damage after myocardial infarctioMyocardial infarctionHartinfarctNL-OMON28497VU University Medical Center20
进行中（未招募）
不适用
OR-SASS is a multi-centre PROBE (prospective randomised, open-label, blinded endpoint) trial, designed to establish the superiority of contrast-enhanced sonothrombolysis given within 4½ hours after stroke onset in consecutively admitted patients with acute ischaemic stroke, as compared with 1) standard iv thrombolysis with tenecteplase (TNK) or alteplase (tPA), and 2) no specific treatment in patients not eligible for thrombolytic treatment.All patients found eligible for thrombolysis may enter the thrombolysis-arm (NOR-SASS I), all patientswith contraindications to thrombolysis within the 4 ½ hour time window may enter the no-thrombolysis-arm(NOR-SASS II).MedDRA version: 14.1Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-000323-41-NOHelse Bergen, Haukeland University Hospital
招募中
不适用
Blood clot dissolution with echocardiogram as initial treatment in acute ST elevation myocardial infarctioCTRI/2020/04/024888Christian medical college and hospital vellore
已完成
不适用
Sonolysis in Risk Reduction of Symptomatic and Silent Brain Infarctions During Coronary StentingCoronary Artery DiseaseNCT02351050University Hospital Ostrava144